3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
5
Sarcoma
1
Gynecologic
1
Conditions
Sarcoma
4
Sarcoma, Ewing
3
Osteosarcoma
3
Liposarcoma
3
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Neuroblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Breast Neoplasms
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma, Kaposi
1
Retinoblastoma
1
Recurrence
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Leiomyosarcoma
1
Hemangiosarcoma
1
Glioma
1
Glioblastoma
1
Ependymoma
1
Colonic Neoplasms
1
Chondrosarcoma
1
Cholangiocarcinoma
1
Acquired Immunodeficiency Syndrome
1
Interventions
pembrolizumab
7
Cyclophosphamide
6
Nivolumab
4
fludarabine
3
spartalizumab
2
aldesleukin
2
Trastuzumab
2
Standard of Care
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Ipilimumab
2
Gemcitabine
2
zanidatamab
1
vocimagene amiretrorepvec
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tinostamustine
1
talazoparib
1
sarilumab
1
sargramostim
1
regorafenib
1
pexidartinib
1
pertuzumab
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
abemaciclib
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled